Cell therapy offers a disease-modifying option for patients w/ refractory autoimmune disease.
Autoimmune disease is a major unmet need
Est. 7M patients in the U.S. with a form of B-cell mediated autoimmune disease (Canaccord Genuity, 2023)
Pathogenic B cells can drive systemic diseases via intrinsic/extrinsic factors.
The effectiveness of current therapies is inadequate:
Often consists of lifelong immune suppression
B-cell-directed agents have limited activity
Recent results with CD19 CAR-T in treating auto-immune diseases look promising
CD19-directed cell therapy is challenging the treatment paradigm for autoimmune diseases
Drug-free remissions after a single treatment in academic trials.
⇨ See below for Mackensen et al. 2022 and Muller 2023 results in lupus (FIG. 1 📸).
FIG. 1. CD19-directed Cell Therapy Potential (early results in autoimmune disease).
If you are interested in cell therapy companies, check out our comprehensive report featuring100’s of biopharma companies specializing in cell therapy products.
🔬 Contract Research Organizations
🧪 Contract Manufacturing Organizations
⚗️ Biopharma vendors looking for new opportunities
🧬 Biopharma professionals at cell & gene therapy companies
Access our free report here: https://www.biopharmiq.com/cell-therapy-companies-report
This article is not investment or legal advice.